Treatment of gout
Full colour PDF of the pages as they appeared in ‘best practice’.
Printer friendly PDF.
KEY ADVISER
Dr Nicola Dalbeth, Rheumatologist and Senior Lecturer, Department of Medicine, University of Auckland
ACKNOWLEDGEMENTS
We are grateful to Dr Peter Gow and Dr Doone Winnard for their review of this article.
Summary points
- Gout is a major cause of arthritis in New Zealand, with high rates of severe disease in Māori and Pacific patients
- Gout causes significant disability in Māori and Pacific men of working age
- All patients with gout should have cardiovascular disease (CVD) risk assessment, and intensive management of modifiable risk factors
- Long-term preventive therapy with allopurinol is critical for effective gout management:
- Prescribe early, before development of tophi
- Monitor serum uric acid levels
- Aim for target serum uric acid <0.36 mmol/L
- Introduce gradually: ‘start low and go slow’
- Use colchicine prophylaxis
- Minimise diuretic therapy in patients with gout
| Page 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Page 1 |


Comments recieved about this article
Comment from:
Stephen Hoskin